Views published in Economic Times regarding Monsanto’s patent rejection order passed by Intellectual Property Appellate Board (IPAB).
BioSpectrum Asia — Debate over compulsory licensing of Bayer’s Nexavar
Full Article: India allows compulsory licensing of Bayer’s Nexavar
Full Article: Patent Opposition in India: Recent Trends
Overview of patent opposition in India, the two-stage patent opposition process and how it affects the industry, as the patent applicants are now vulnerable to…
By 2020, according to Frost & Sullivan, healthcare expenditure in the APAC will increase 151 percent over 2010 figure, to $2927 billion at a compound annual growth rate of 9.2 percent.